11LS | pdb_000011ls

Human Monoclonal Antibody RVC68 in complex with rabies virus glycoprotein

• PDB DOI: https://doi.org/10.2210/pdb11LS/pdb
• EM Map EMD-75815: EMDB EMDataResource

• Classification: VIRAL PROTEIN
• Organism(s): Homo sapiens, Lyssavirus rabies
• Expression System: Drosophila melanogaster, Homo sapiens
• Mutation(s): No 


• Deposited: 2026-03-03 Released: 2026-08-19 
• Deposition Author(s): Callaway, H.M., Zyla, D., Hastie, K., Harkins, S., Kothalawalage, S., Samarasinghe, S., Flynn, A., Hariharan, C., Yin, J., Corti, D., Bouhry, H., Dessain, S., Saphire, E.O.
• Funding Organization(s): Other private

---

Experimental Data Snapshot

• Method: ELECTRON MICROSCOPY
• Resolution: 3.15 Å
• Aggregation State: PARTICLE 
• Reconstruction Method: SINGLE PARTICLE 

Literature

Antigenic landscape of rabies and related lyssaviruses revealed by cryo-EM.

Callaway, H.M., Zyla, D.S., Hastie, K.M., Harkins, S.S., Kothalawalage, S., Samarasinghe, N., Flynn, A., Hariharan, C., Yin, J., Corti, D., Bourhy, H., Dessain, S.K., Saphire, E.O.

(2026) Cell Rep 45: 117993-117993

• PubMed: 42758589 
• DOI: https://doi.org/10.1016/j.celrep.2026.117993
• Primary Citation Related Structures: 
  11IW, 11LP, 11LQ, 11LR, 11LS


• PubMed Abstract: 
  

  Rabies continues to kill over 60,000 people per year despite life-saving vaccines and post-exposure treatments and costs billions of dollars in prevention and treatment. Preventing rabies deaths and reducing the global economic burden of the virus will require both developing a monoclonal antibody cocktail to replace human serum in treatment and improving rabies vaccines to elicit long-lasting protection. Here, we solve nine cryo-electron microscopy (cryo-EM) structures of neutralizing monoclonal antibodies (mAbs) in complex with the rabies virus glycoprotein (RABV-G). The nine structures span three known antigenic sites plus two additional antigenic sites, not among the five classically identified sites. We find that these antigenic sites, V and VI, are broadly cross-reactive across lyssaviruses, whereas immunodominant sites II/IV and III are rabies specific. Across the mAb panel, fusion inhibition and binding affinity correlate best with neutralization. Together, these results provide a roadmap for structure-guided vaccine and therapeutic antibody design for rabies and related lyssaviruses.

---

Organizational Affiliation: 
• Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59717, USA; Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA. Electronic address: [e-mail].
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Institut Pasteur, Université Paris Cité, Unit of Lyssavirus Epidemiology and Neuropathology, World Health Organization Collaborating Centre for Reference and Research on Rabies, Paris, France.
Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA.
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 5-mer - A1B1C1D1E1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 5-mer - A4B1 

Biological assembly 1 assigned by authors.

Biological Assembly Evidence: electron microscopy

Macromolecule Content 

• Total Structure Weight: 155.52 kDa 
• Atom Count: 6,505 
• Modeled Residue Count: 836 
• Deposited Residue Count: 1,426 
• Unique protein chains: 5

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal Antibody RVA122 Heavy Chain	A [auth E]	265	Homo sapiens	Mutation(s): 0

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Glycoprotein	B [auth A]	468	Lyssavirus rabies	Mutation(s): 0
UniProt
Find proteins for P08667 (Rabies virus (strain Pasteur vaccins / PV)) Explore P08667  Go to UniProtKB:  P08667
Glycosylation
Glycosylation Sites: 2

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal Antibody RVA122 Light Chain	C [auth D]	217	Homo sapiens	Mutation(s): 0

Entity ID: 4
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal Antibody RVC68 Heavy Chain	D [auth H]	262	Homo sapiens	Mutation(s): 0

Entity ID: 5
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal Antibody RVC68 Light Chain	E [auth L]	214	Homo sapiens	Mutation(s): 0

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
NAG	F [auth A], G [auth A]	2-acetamido-2-deoxy-beta-D-glucopyranose C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

• Method: ELECTRON MICROSCOPY
• Resolution: 3.15 Å
• Aggregation State: PARTICLE 
• Reconstruction Method: SINGLE PARTICLE 

EM Software:

Task	Software Package	Version
MODEL REFINEMENT	PHENIX
RECONSTRUCTION	cryoSPARC

Structure Validation

Entry History 

& Funding Information

Deposition Data

• Released Date: 2026-08-19 
Deposition Author(s): Callaway, H.M., Zyla, D., Hastie, K., Harkins, S., Kothalawalage, S., Samarasinghe, S., Flynn, A., Hariharan, C., Yin, J., Corti, D., Bouhry, H., Dessain, S., Saphire, E.O.

---

Funding Organization	Location	Grant Number
Other private	United States	--
Other private	United States	--

Revision History  

• Version 1.0: 2026-08-19
  Type: Initial release
  
• Version 1.1: 2026-09-30
  Changes: Data collection, Database references